An2 Therapeutics Inc (ANTX) Stock Price, Quote & News

Company Profile

AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chag...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 331 9090

Website: www.an2therapeutics.com

Address:

1800 El Camino Real, Suite D, Menlo Park, United States

PLATINUM_TRADES Jun. 18 at 2:06 AM

$ANTX another good day on overnight swings for us with all winners.... Now we took this one for tomorrow small float big volume.. $1.21 major resistance breaks this should head for $1.55 next leg up 🚨 🚨

0 · Reply

JK_Capital Jun. 17 at 4:51 PM

$ANTX is looking good here for a swing with major catalysts ahead. Strong cash position for 3+ years runway and multiple data readouts. Potential for non dilutive funding as well. This is primed to bounce $CERO $ACXP $RBNE

0 · Reply

TheDihhTator Jun. 12 at 8:49 PM

$ANTX see this one going to $3 EOW

0 · Reply

JK_Capital Jun. 12 at 5:58 PM

$ANTX couple members of management held roles in Anacor Pharmaceuticals, which was bought out by Pfizer for $5.2B. Management has had successful prior experience with boron based drugs $NCNA $HCTI $KLTO

1 · Reply

JK_Capital Jun. 12 at 5:39 PM

$ANTX liking this stock here. Couple catalysts coming with data readouts set for next couple months Non dilutive funding news is imminent, could be some major partnership with big pharma, with an upfront payment + milestone structure🚀 $NCNA $HCTI $KLTO

1 · Reply

Stmkr Jun. 11 at 11:53 AM

$ANTX It is going to be a while until another catalyst but the platform remains very promising. I wonder if ANTX might surprise with a partnership announcement for one of each programs.

0 · Reply

CEOBuysDisclosures Jun. 3 at 10:50 PM

$ANTX CEO purchased 10,000 shares at $1.07 for a total of $10,665. Easom Eric now owns 1,516,262 shares. https://ceo-buys.com

0 · Reply

Redposition May. 28 at 11:52 PM

$ANTX 2.5M shares traded today. Any info ?

0 · Reply

anachartanalyst May. 5 at 2:02 PM

$ANTX https://anachart.com/wp-content/uploads/ana_temp/1746453714_soc-img.jpg

0 · Reply

Stmkr May. 2 at 4:32 AM

$ANTX Lucky I was out. I did not expect this. Great cash runway but no big catalyst any time soon.

0 · Reply

AN2 Therapeutics Announces Poster Presentation Highlighting M. Abscessus Data at 2025 Colorado Mycobacteria Conference

May 13, 2025, 4:01 PM EDT - 6 weeks ago

AN2 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business and Scientific Highlights

May 1, 2025, 4:00 PM EDT - 2 months ago

AN2 Therapeutics Reports Data from the Phase 3 Portion of Previously Terminated EBO-301 Study and Outlines Future Milestones from Boron Chemistry Pipeline

Apr 30, 2025, 7:00 AM EDT - 2 months ago

AN2 Therapeutics to Participate in Citizens JMP Life Sciences Conference

Mar 25, 2025, 4:00 PM EDT - 3 months ago

AN2 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business and Scientific Highlights

Mar 3, 2025, 4:00 PM EST - 4 months ago

AN2 Therapeutics to Present at Leerink Partners Global Healthcare Conference

$AN2 Provides Strategic Update for Phase 3 EBO-301 Trial in Treatment Refractory MAC Lung Disease$

Feb 24, 2025, 7:00 AM EST - 4 months ago

AN2 Provides Strategic Update for Phase 3 EBO-301 Trial in Treatment Refractory MAC Lung Disease

Feb 20, 2025, 7:00 AM EST - 4 months ago

AN2 Therapeutics to Participate at Upcoming Investor Conferences

Jan 29, 2025, 4:00 PM EST - 5 months ago

AN2 Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Nov 13, 2024, 4:00 PM EST - 8 months ago

AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline

Oct 17, 2024, 7:00 AM EDT - 9 months ago

AN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (caused by Mycobacterium tuberculosis) and Malaria

Aug 28, 2024, 4:00 PM EDT - 10 months ago

AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 16, 2024, 7:00 AM EDT - 11 months ago

AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan

Aug 13, 2024, 4:01 PM EDT - 11 months ago

AN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific Highlights

$AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung Disease$

Aug 8, 2024, 4:30 PM EDT - 11 months ago

AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung Disease

May 14, 2024, 4:01 PM EDT - 1 year ago

AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights

Mar 28, 2024, 4:10 PM EDT - 1 year ago

AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights

Feb 12, 2024, 6:56 AM EST - 1 year ago

AN2 Therapeutics to pause lung disease study enrollment

$AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease$

Feb 12, 2024, 6:45 AM EST - 1 year ago

AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease

Jan 30, 2024, 4:10 PM EST - 1 year ago

AN2 Therapeutics to Present at Oppenheimer Healthcare Life Sciences Conference

Nov 9, 2023, 4:05 PM EST - 1 year ago

AN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific Highlights

Nov 6, 2023, 7:00 AM EST - 1 year ago

AN2 Therapeutics to Present at Upcoming Investor Conferences

Oct 18, 2023, 7:00 AM EDT - 1 year ago

AN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas Disease

Oct 11, 2023, 12:01 AM EDT - 1 year ago

AN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023

Sep 26, 2023, 7:00 AM EDT - 1 year ago

AN2 Therapeutics Signs Grant Agreement to Discover Novel, Boron Based Therapies for Tuberculosis and Malaria

$AN2 Therapeutics commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium complex (MAC) Lung Disease$

Sep 13, 2023, 7:00 AM EDT - 1 year ago

AN2 Therapeutics commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium complex (MAC) Lung Disease

Aug 15, 2023, 10:42 PM EDT - 2 years ago

AN2 Therapeutics Announces Pricing of $70.0 Million Underwritten Offering of Common Stock

Aug 10, 2023, 4:10 PM EDT - 2 years ago

AN2 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights

May 25, 2023, 4:10 PM EDT - 2 years ago

AN2 Therapeutics to Present at Jefferies Healthcare Conference

May 11, 2023, 4:10 PM EDT - 2 years ago

AN2 Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights

May 5, 2023, 1:55 PM EDT - 2 years ago

AN2 Therapeutics: Boron Chemistry For Infectious Diseases

May 1, 2023, 7:00 AM EDT - 2 years ago

AN2 Therapeutics to Present at JMP Securities Life Sciences Conference

Mar 29, 2023, 4:01 PM EDT - 2 years ago

AN2 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights

Feb 28, 2023, 4:10 PM EST - 2 years ago

AN2 Therapeutics to Participate in Upcoming Investor Conferences

Jan 31, 2023, 4:10 PM EST - 2 years ago

AN2 Therapeutics to Present at SVB Securities Global Biopharma Conference

Nov 9, 2022, 4:05 PM EST - 2 years ago

AN2 Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates

Oct 19, 2022, 8:00 AM EDT - 2 years ago

AN2 Therapeutics to Present New Epetraborole Data at IDWeek 2022

$AN2 Therapeutics Provides Update on Epetraborole Ex-U.S. Development Plan in Treatment-Refractory MAC Lung Disease$

Oct 6, 2022, 7:00 AM EDT - 2 years ago

AN2 Therapeutics Provides Update on Epetraborole Ex-U.S. Development Plan in Treatment-Refractory MAC Lung Disease

Sep 29, 2022, 7:00 AM EDT - 2 years ago

NIH Awards Contract to AN2 Therapeutics Valued Up to $17.8 Million

Aug 29, 2022, 7:00 AM EDT - 3 years ago

AN2 Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference

Aug 11, 2022, 4:10 PM EDT - 3 years ago

AN2 Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates

$AN2 Therapeutics Initiates Pivotal Phase 2/3 Trial Evaluating Epetraborole for Treatment-Refractory MAC Lung Disease$

Jun 29, 2022, 7:00 AM EDT - 3 years ago

AN2 Therapeutics Initiates Pivotal Phase 2/3 Trial Evaluating Epetraborole for Treatment-Refractory MAC Lung Disease

May 10, 2022, 4:10 PM EDT - 3 years ago

AN2 Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates

May 9, 2022, 7:00 AM EDT - 3 years ago

AN2 Therapeutics Appoints Maggie FitzPatrick to Its Board of Directors

PLATINUM_TRADES Jun. 18 at 2:06 AM

0 · Reply

JK_Capital Jun. 17 at 4:51 PM

0 · Reply

TheDihhTator Jun. 12 at 8:49 PM

$ANTX see this one going to $3 EOW

0 · Reply

JK_Capital Jun. 12 at 5:58 PM

1 · Reply

JK_Capital Jun. 12 at 5:39 PM

1 · Reply

Stmkr Jun. 11 at 11:53 AM

$ANTX It is going to be a while until another catalyst but the platform remains very promising. I wonder if ANTX might surprise with a partnership announcement for one of each programs.

0 · Reply

CEOBuysDisclosures Jun. 3 at 10:50 PM

$ANTX CEO purchased 10,000 shares at $1.07 for a total of $10,665. Easom Eric now owns 1,516,262 shares. https://ceo-buys.com

0 · Reply

Redposition May. 28 at 11:52 PM

$ANTX 2.5M shares traded today. Any info ?

0 · Reply

anachartanalyst May. 5 at 2:02 PM

$ANTX https://anachart.com/wp-content/uploads/ana_temp/1746453714_soc-img.jpg

0 · Reply

Stmkr May. 2 at 4:32 AM

$ANTX Lucky I was out. I did not expect this. Great cash runway but no big catalyst any time soon.

0 · Reply

Coster May. 1 at 8:51 PM

$ANTX tomorrow < 0.9

0 · Reply

MillionTrader_xy May. 1 at 8:11 PM

$ANTX burning money only

0 · Reply

MillionTrader_xy May. 1 at 8:07 PM

$ANTX fail

0 · Reply

ka1954 Apr. 9 at 2:52 PM

$ANTX what luck? last year this fucker didn't do anything, now market crashing, and another excuse to go down

0 · Reply

NYgostock Apr. 7 at 4:55 PM

$ANTX

0 · Reply

bull130 Apr. 1 at 1:48 PM

$ANTX Can this run 20% at least? What a 💩

0 · Reply

ka1954 Mar. 31 at 1:52 PM

$ANTX just because markets are selling, u guys are selling this stock. but where were u when market was skyrocketing last year. LOL

0 · Reply

ka1954 Mar. 26 at 2:04 PM

$ANTX this one has been dead for so long, most people have given up hope.

0 · Reply

JarvisFlow Mar. 26 at 1:07 PM

Citizens Capital Markets has updated their rating for AN2 Therapeutics ( $ANTX ) to Market Outperform with a price target of 5.

0 · Reply

FORMER Mar. 26 at 9:35 AM

$ANTX On 11/20 Institutional Shares were 13,764,229 - 46.12% and today (3/26) Institutional Shares are now 13,764,229 - 46.12% 🤙

0 · Reply

Market Cap	32.59M
Revenue (ttm)	0.00
Net Income (ttm)	-51.32M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	51,200
Avg Vol	255,660
Day's Range	N/A - N/A
Shares Out	30.18M
Stochastic %K	8%
Beta	-0.08
Analysts	Hold
Price Target	$1.67